CLEVELAND, April 11, 2019 /PRNewswire/ -- ViewRay, Inc.
(Nasdaq: VRAY) announced today details relating to the release of
its first quarter 2019 financial results.
ViewRay will hold a conference call to discuss results on
Thursday, May 2, 2019 at 4:30 p.m. ET / 1:30 p.m.
PT. The dial-in numbers are (844) 277-1426 for domestic
callers and (336) 525-7129 for international callers. The
conference ID number is 8616638. A live webcast of the conference
call will be available on the investor relations page of ViewRay's
corporate website at www.viewray.com.
After the live webcast, a replay of the webcast will remain
available online on the investor relations page of ViewRay's
corporate website, www.viewray.com, for 14 days following the call.
In addition, a telephonic replay of the call will be available
until May 9, 2019. The replay dial-in
numbers are (855) 859-2056 for domestic callers and (404) 537-3406
for international callers. Please use the conference ID number
8616638.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY), designs,
manufactures and markets the MRIdian® radiation therapy system.
MRIdian is built upon a proprietary high-definition MR imaging
system designed from the ground up to address the unique challenges
and clinical workflow for advanced radiation oncology. Unlike MR
systems used in diagnostic radiology, MRIdian's high-definition MR
was purposely built to deliver high-precision radiation without
unnecessary beam distortion, and consequently, help to mitigate
skin toxicity and other safety concerns that may otherwise arise
when high magnetic fields interact with radiation beams. ViewRay
and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release
contains forward-looking statements within the meaning of Section
27A of the Private Securities Litigation Reform Act. Statements in
this press release that are not purely historical are
forward-looking statements. Such forward-looking statements
include, among other things, the rate of new orders, upgrades and
installations, ViewRay's financial guidance for the full year 2019
and ViewRay's conference call to discuss its fourth quarter and
year to date results. Actual results could differ from those
projected in any forward-looking statements due to numerous
factors. Such factors include, among others, the ability to
commercialize MRIdian Linac System, demand for ViewRay's products,
the ability to convert backlog into revenue, and the timing of
delivery of ViewRay's products, the timing, results and other
uncertainties associated with clinical trials, the ability to raise
the additional funding needed to continue to pursue ViewRay's
business and product development plans, the inherent uncertainties
associated with developing new products or technologies,
competition in the industry in which ViewRay operates and overall
market conditions. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to ViewRay's business in general, see ViewRay's current
and future reports filed with the Securities and Exchange
Commission, including its Annual Report on Form 10-K for the fiscal
year ended December 31, 2018, as
updated periodically with the company's other filings with the SEC.
These forward-looking statements are made as of the date of this
press release, and ViewRay assumes no obligation to update the
forward-looking statements, or to update the reasons why actual
results could differ from those projected in the forward-looking
statements, except as required by law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/viewray-announces-conference-call-and-webcast-of-first-quarter-2019-financial-results-to-be-held-after-market-on-may-2-2019-300830009.html
SOURCE ViewRay, Inc.